Urigen's pipeline includes URG101, targeting the treatment of painful bladder syndrome (PBS), symptoms of pelvic bladder syndrome secondary to pelvic irradiation and dyspareunia; URG301, targeting acute urgency in patients diagnosed with overactive bladder, acute urethral discomfort and urethritis; and URG302, a follow-on program targeting acute urgency in patients diagnosed with overactive bladder.
View the product pipeline

May 17-22, 2008, Orlando, Florida - Visit Urigen's booth #3847 at the American Urological Association (AUA) 2008 Annual Meeting. Click here.

Apr 25 2008 - Urigen Announces US Patent Office Notice of Allowance of Claims for URG101

Apr 9 2008 - FDANews: Urigen Candidate Demonstrates Positive Results in Trial

Apr 7 2008 - Urigen Announces Early Closure of URG101 Phase II Clinical Trial based on Positive Interim Analysis Results

Apr 4 2008 - Announcement of Urigen Pharmaceuticals, Inc.

Mar 12 2008 - Urigen Announces Positive Phase II Clinical Trial Results with URG101
Archives

Urigen Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative products for urology indications. Urigen has two primary programs in development that are either in or positioned to enter Phase II clinical trials.